BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//EAHAD - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:EAHAD
X-ORIGINAL-URL:https://www.eahad.org
X-WR-CALDESC:Events for EAHAD
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260615T170000
DTEND;TZID=Europe/Brussels:20260615T180000
DTSTAMP:20260724T000626
CREATED:20260406T150040Z
LAST-MODIFIED:20260507T083021Z
UID:30990-1781542800-1781546400@www.eahad.org
SUMMARY:Inhibitor Development in Gene Therapy for Haemophilia
DESCRIPTION:Gene therapy is transforming the treatment landscape of hemophilia\, but major questions remain regarding its use in patients with current or past inhibitors. In this webinar\, leading experts will discuss the most challenging clinical and immunological questions\, from mechanisms of liver-induced tolerance to the management of inhibitors developing after gene transfer\, and will debate whether eligibility criteria should evolve in light of emerging data.
URL:https://www.eahad.org/event/inhibitor-development-in-gene-therapy-for-haemophilia/
LOCATION:Online
CATEGORIES:2026,EAHAD Events,Events
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260407T173000
DTEND;TZID=Europe/Brussels:20260407T183000
DTSTAMP:20260724T000626
CREATED:20260409T132716Z
LAST-MODIFIED:20260507T083028Z
UID:30976-1775583000-1775586600@www.eahad.org
SUMMARY:Clinical Implications of Roctavian’s Market Withdrawal
DESCRIPTION:The recent withdrawal of Roctavian from the market has raised important questions for clinicians\, patients\, and healthcare systems involved in the management of haemophilia A gene therapy. As the first approved GT  medicine for adults with severe haemophilia A\, Roctavian represented a significant milestone in the evolution of treatment options\, and the effects of its withdrawal remain to be seen. This online session explores the clinical implications of its withdrawal\, including considerations for patient management\, ongoing monitoring of treated individuals\, and the broader impact on the future of gene therapy in haemophilia. \n\n\n\n\nWatch this insightful discussion on what this development means for clinical practice and the haemophilia community.
URL:https://www.eahad.org/event/clinical-implications-of-roctavians-market-withdrawal/
LOCATION:Online
CATEGORIES:2026,EAHAD Events,Events
END:VEVENT
END:VCALENDAR